BR112013026202A2 - composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank - Google Patents
composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tankInfo
- Publication number
- BR112013026202A2 BR112013026202A2 BR112013026202A BR112013026202A BR112013026202A2 BR 112013026202 A2 BR112013026202 A2 BR 112013026202A2 BR 112013026202 A BR112013026202 A BR 112013026202A BR 112013026202 A BR112013026202 A BR 112013026202A BR 112013026202 A2 BR112013026202 A2 BR 112013026202A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- ikk
- kinase
- epsilon
- therapeutic uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
resumo da patente de invenção para: “composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank”. a invenção se refere a compostos, composições farmacêuticas e medicamentos compreendendo tais compostos, e o uso destes compostos, composições e medicamentos em métodos de tratamento de doenças e distúrbios
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161474366P | 2011-04-12 | 2011-04-12 | |
PCT/US2012/033384 WO2012142329A1 (en) | 2011-04-12 | 2012-04-12 | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013026202A2 true BR112013026202A2 (pt) | 2017-07-25 |
Family
ID=47009699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013026202A BR112013026202A2 (pt) | 2011-04-12 | 2012-04-12 | composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank |
Country Status (10)
Country | Link |
---|---|
US (1) | US20140288044A1 (pt) |
EP (1) | EP2696683A4 (pt) |
JP (1) | JP2014510794A (pt) |
KR (1) | KR20140048873A (pt) |
CN (1) | CN103732067A (pt) |
AU (1) | AU2012242777A1 (pt) |
BR (1) | BR112013026202A2 (pt) |
CA (1) | CA2832919A1 (pt) |
MX (1) | MX2013011908A (pt) |
WO (1) | WO2012142329A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
DE102011112978A1 (de) * | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
GB201303109D0 (en) * | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
CN104297354B (zh) * | 2013-07-16 | 2016-07-06 | 重庆市康乾医药有限公司 | 一种高效液相色谱法测定盐酸戊乙奎醚中杂质的检测方法 |
CA2932608C (en) | 2013-12-11 | 2023-02-14 | Biogen Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
AU2014373773C1 (en) * | 2014-01-01 | 2019-06-27 | Medivation Technologies Llc | Compounds and methods of use |
TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
CN104090037B (zh) * | 2014-06-20 | 2015-12-30 | 成都力思特制药股份有限公司 | 一种盐酸戊乙奎醚的降解产物的检测方法 |
CN104020230B (zh) * | 2014-06-20 | 2015-07-15 | 成都力思特制药股份有限公司 | 一种用于检测盐酸戊乙奎醚中副产物的方法 |
ES2727376T3 (es) * | 2014-09-26 | 2019-10-15 | Gilead Sciences Inc | Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK |
CN107207475A (zh) | 2014-10-16 | 2017-09-26 | 拜耳医药股份有限公司 | 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物 |
EP3356373B1 (en) | 2015-09-29 | 2020-02-19 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic sulfondiimine compounds |
JP6888000B2 (ja) | 2015-10-08 | 2021-06-16 | バイエル ファーマ アクチエンゲゼルシャフト | 新規な修飾された大環状化合物 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
CN108430993A (zh) | 2015-12-17 | 2018-08-21 | 吉利德科学公司 | Tank-结合激酶抑制剂化合物 |
CN106928216A (zh) * | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
EP3190103A1 (en) * | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
WO2017125534A1 (en) * | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
AU2017209935B2 (en) | 2016-01-22 | 2021-04-01 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as NIK inhibitors |
EP3478675B1 (en) | 2016-06-30 | 2020-04-22 | Janssen Pharmaceutica NV | Heteroaromatic derivatives as nik inhibitors |
CN109689645B (zh) | 2016-06-30 | 2022-06-03 | 杨森制药有限公司 | 作为nik抑制剂的氰基吲哚啉衍生物 |
GB201702947D0 (en) | 2017-02-23 | 2017-04-12 | Domainex Ltd | Novel compounds |
WO2018177889A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
ES2900199T3 (es) | 2017-03-28 | 2022-03-16 | Bayer Ag | Novedosos compuestos macrocíclicos inhibidores de PTEFB |
SG11202003441VA (en) * | 2017-10-17 | 2020-05-28 | Merck Patent Gmbh | PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF |
AU2018352699A1 (en) * | 2017-10-17 | 2020-05-28 | Merck Patent Gmbh | Pyrimidine TBK/IKKE inhibitor compounds and uses thereof |
EA202091894A1 (ru) | 2018-02-13 | 2020-12-28 | Байер Акциенгезельшафт | Применение 5-фтор-4-(4-фтор-2-метоксифенил)-n-{4-[(s-метилсульфонимидоил)метил]пиридин-2-ил}пиридин-2-амина для лечения диффузной в-крупноклеточной лимфомы |
WO2020206588A1 (en) * | 2019-04-08 | 2020-10-15 | Lynk Pharmaceuticals Co., Ltd. | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
CN115677663A (zh) * | 2022-10-25 | 2023-02-03 | 上海朴颐化学科技有限公司 | 一种拉米地坦中间体的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0317841D0 (en) * | 2003-07-30 | 2003-09-03 | Cyclacel Ltd | Compound |
BRPI0412347A (pt) * | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | 2-aminofenil-4-fenilpiridinas como inibidores de quinase |
FR2911139A1 (fr) * | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
PT2200436E (pt) * | 2007-09-04 | 2015-04-29 | Scripps Research Inst | Pirimidinilaminas substituídas como inibidoras da proteína quinase |
WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
CA2777762A1 (en) * | 2009-10-12 | 2011-04-21 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon |
GB201012105D0 (en) * | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
AU2011328237A1 (en) * | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
-
2012
- 2012-04-12 CN CN201280028694.9A patent/CN103732067A/zh active Pending
- 2012-04-12 KR KR1020137029898A patent/KR20140048873A/ko not_active Application Discontinuation
- 2012-04-12 BR BR112013026202A patent/BR112013026202A2/pt not_active IP Right Cessation
- 2012-04-12 US US14/112,847 patent/US20140288044A1/en not_active Abandoned
- 2012-04-12 CA CA2832919A patent/CA2832919A1/en not_active Abandoned
- 2012-04-12 AU AU2012242777A patent/AU2012242777A1/en not_active Abandoned
- 2012-04-12 JP JP2014505312A patent/JP2014510794A/ja active Pending
- 2012-04-12 WO PCT/US2012/033384 patent/WO2012142329A1/en active Application Filing
- 2012-04-12 MX MX2013011908A patent/MX2013011908A/es not_active Application Discontinuation
- 2012-04-12 EP EP12771276.8A patent/EP2696683A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2014510794A (ja) | 2014-05-01 |
EP2696683A1 (en) | 2014-02-19 |
US20140288044A1 (en) | 2014-09-25 |
KR20140048873A (ko) | 2014-04-24 |
CA2832919A1 (en) | 2012-10-18 |
EP2696683A4 (en) | 2014-08-13 |
CN103732067A (zh) | 2014-04-16 |
MX2013011908A (es) | 2014-03-27 |
AU2012242777A1 (en) | 2013-10-31 |
WO2012142329A1 (en) | 2012-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013026202A2 (pt) | composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank | |
PH12017500166A1 (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
UA111588C2 (uk) | Композиція інгібітора jak для місцевого застосування | |
MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
MX343534B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
MX343688B (es) | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. | |
EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
MX2014000779A (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide. | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
BR112013032720A2 (pt) | "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados" | |
JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
AU2012253759A8 (en) | Tricyclic sulfonamide compounds and methods of making and using same | |
EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
BR112014004447A2 (pt) | bifenilcarboxamidas como inibidores de quinase rock | |
EA201370230A1 (ru) | Новые ингибиторы rock | |
MX2014000963A (es) | Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide. | |
TN2010000266A1 (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure | |
MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |